- Home
- About
- Section Advisors
- Meet Our Field Medical Affairs Team
- Speakers Bureau
- Supporting Organizations
- Contact Us
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Infographics
- Learning Tracks
- Podcasts
- Shareable/Downloadable Content
- Videos
- Monthly Spotlight
- PsychUSim
- PsychU Roleplay
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Psychiatric Scales
- Psychopharmacology
- Supporting Organizations
- Mental Health Month
Virtual Event – Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
This is a Virtual Event for PsychU members in Connecticut, Delaware, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, and Vermont.
Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin. The speakers will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia.
Objectives:
- Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
- Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
- Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology
Featuring
Jehan Marino, PharmD, BCPP (OPDC)
Clinical & Scientific Director
Mark Tacelosky, PharmD (OPDC)
Clinical & Scientific Liaison
Speakers Jehan Marino, PharmD, BCPP and Mark Tacelosky, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Registration
Related Resources
-
Working With People In Crisis For First Responders
Downloadable Resource May 18, 2023Download Infographic
-
Agitation Associated With Alzheimer’s Dementia: Mechanism Of Disease
Video May 16, 2023Research has shown that in patients with Alzheimer’s dementia, agitation is associated with tau pathology and neurodegeneration in the prefrontal cortex and amygdala regions of the brain.
-
Hot Topics: Clinical Questions in Schizophrenia – Question III
Interview May 15, 2023Dr. Christoph U. Correll will address current and relevant clinical questions relating to schizophrenia. These questions and Dr. Correll’s response will be recorded and released as short videos. When…
Join today for instant access to all PsychU content, events, and more!
Membership is free!
Join PsychU Today to receive a wide array of tools and benefits
- Join our multidisciplinary community that is improving mental health care… together
- Quickly learn more about the topics you're interested in
- Access an award-winning library of on-demand mental health resources
- Gain key insights from industry expert & thought leaders
Stay Connected: